← Search & browse all drugs
ALIMENTARY TRACT AND METABOLISM › DRUGS FOR ACID RELATED DISORDERS › DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) › Proton pump inhibitors
tegoprazan
A02BC09
Forms & Strengths
- Oral tablet: 50 mg
- Oral tablet: 100 mg
Adult Dosing
- Erosive esophagitis: 50 mg to 100 mg orally once daily for up to 4 to 8 weeks
- Gastric ulcer: 50 mg orally once daily for up to 8 weeks
- Helicobacter pylori eradication: 50 mg to 100 mg twice daily as part of combination therapy
Pediatric Dosing
- Safety and efficacy in pediatric patients under 18 years have not been established
Indications
- Treatment of erosive esophagitis
- Treatment of gastric ulcers
- Eradication of Helicobacter pylori in combination with appropriate antibiotics
Mechanism of Action
- Potassium-competitive acid blocker (P-CAB)
- Reversibly inhibits the H+/K+-ATPase pump in gastric parietal cells
- Suppresses gastric acid secretion rapidly and independently of the proton pump activation state
Contraindications
- Hypersensitivity to tegoprazan or any component of the formulation
- Concomitant use with rilpivirine-containing products
Adverse Reactions
- Diarrhea
- Nausea
- Abdominal pain
- Constipation
- Headache
- Nasopharyngitis
Drug Interactions
- Drugs dependent on gastric pH for absorption (e.g., ketoconazole, iron salts, itraconazole) may have decreased bioavailability
- CYP3A4 inhibitors may increase plasma concentrations of tegoprazan
- CYP3A4 inducers may decrease plasma concentrations of tegoprazan
Curated Content: Needs Vetting Before Put to Clinical Use